Text Size

Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study

Labetoulle M., Leonardi A., Amrane M., Ismail D., Garrigue J.-S., Garhöfer G., de la Maza M.S., Baudouin C.


  • 2018
  • Clinical Therapeutics
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Technology

    Drug Delivery

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Bicêtre Hospital, AP-HP, Paris-Sud University, Le Kremlin-Bicêtre, France; Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy; Santen SAS, Evry, France; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Institute Clinic of Ophthalmology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Quinze-Vingts National Ophthalmology Hospital, Paris, France; UPMC University, Paris 6, Vision Institute, INSERM UMRS968, CNRS UMR7210, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022